Rhythm Pharmaceuticals/$RYTM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
- Ticker
- $RYTM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 414
- Headquarters
- Boston, United States
- Website
- rhythmtx.com
RYTM Metrics
BasicAdvanced
$6.2B
-
-$3.12
1.97
-
Price and volume
Market cap
$6.2B
Beta
1.97
52-week high
$122.20
52-week low
$74.50
Average daily volume
685K
Financial strength
Current ratio
3.452
Quick ratio
3.004
Long term debt to equity
0.444
Total debt to equity
0.505
Interest coverage (TTM)
-10.86%
Profitability
EBITDA (TTM)
-199.55
Gross margin (TTM)
89.00%
Net profit margin (TTM)
-85.59%
Operating margin (TTM)
-83.62%
Effective tax rate (TTM)
-0.52%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-30.96%
Return on equity (TTM)
-117.04%
Valuation
Price to revenue (TTM)
25.198
Price to book
59.9
Price to tangible book (TTM)
62.89
Price to free cash flow (TTM)
-41.321
Free cash flow yield (TTM)
-2.42%
Free cash flow per share (TTM)
-2.169
Growth
Revenue change (TTM)
53.51%
Earnings per share change (TTM)
3.21%
3-year revenue growth (CAGR)
76.32%
3-year earnings per share growth (CAGR)
-1.82%
10-year earnings per share growth (CAGR)
3.33%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
Analyst projections of the future price of Rhythm Pharmaceuticals stock.
Bulls say / Bears say
IMCIVREE sales reached $71.3 million in the second quarter, up 19% sequentially, while the number of patients on reimbursed treatment grew by more than 20%. That points to growing demand across its existing markets and the new US launch. (Rhythm Pharmaceuticals)
The Phase 3 TRANSCEND trial showed a 19.8% placebo-adjusted reduction in BMI at 52 weeks for patients with acquired hypothalamic obesity. This provides strong clinical evidence for an indication with significant unmet need. (GlobeNewswire)
IMCIVREE has gained approval for acquired hypothalamic obesity in Japan and Canada, adding potential markets beyond the US. These approvals could support further international growth as the company pursues launches and reimbursement. (GlobeNewswire, Investor.Wedbush)
All product revenue currently depends on IMCIVREE, yet Rhythm reported a $49.3 million net loss in the second quarter despite $71.3 million of sales. A setback to the drug or its market access would therefore hit the whole commercial business while the company remains loss-making. (Rhythm Pharmaceuticals)
The more than 400 patient start forms for acquired hypothalamic obesity did not all represent patients who had completed reimbursement and begun treatment. By quarter-end, coverage policies reached about 25% of Medicaid lives and 35% of commercial lives, leaving launch growth reliant on converting interest into covered therapy. (Longbridge)
RM-718's encouraging acquired hypothalamic obesity result is still preliminary: the reported 11.6% mean BMI reduction at 16 weeks came from only seven patients. That small early-stage dataset leaves considerable uncertainty about whether the candidate can deliver consistent results in larger trials. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
Upcoming events
No upcoming events
RYTM News
AllArticlesVideos
Funds containing RYTM
AllUSDEURGBP
Fund name | Fund size | $RYTM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.57% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.57% |
iShares Healthcare Innovation£DRDR | £1B | 0.57% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.41% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.41% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.